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Abstract  32 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is predominantly caused by 33 
heterozygous missense variants in the cardiac ryanodine receptor, RYR2. However, many RYR2 34 
missense variants are classified as variants of uncertain significance (VUS). We systematically re-35 
evaluated all RYR2 variants in healthy individuals and those with CPVT or arrhythmia using the 2015 36 
American College of Medical Genomics guidelines. RYR2 variants were identified by the NW 37 
Genomic Laboratory Hub, from the published literature and databases of sequence variants. Each 38 
variant was assessed based on minor allele frequencies, in silico prediction tools and appraisal of 39 
functional studies and classified according to the ACMG-AMP guidelines. Phenotype data was 40 
collated where available. Of the 326 identified RYR2 missense variants, 55 (16.9%), previously 41 
disease-associated variants were re-classified as benign. Application of the gnomAD database of 42 
>140,000 controls allowed reclassification of 11 variants more than the ExAC database. CPVT-43 
associated RYR2 variants clustered predominantly between amino acid positions 3949-4332 and 44 
4867-4967 as well as the RyR and IP3R homology associated and ion transport domains (P < 0.005). 45 
CPVT-associated RYR2 variants occurred at more conserved amino acid positions compared to 46 
controls, and variants associated with sudden death had higher conservation scores (P < 0.005). 47 
There were five potentially pathogenic RYR2 variants associated with sudden death during sleep 48 
which were located almost exclusively in the C-terminus of the protein. In conclusion, control 49 
sequence databases facilitate reclassification of RYR2 variants but the majority remain as VUS. 50 
Notably, pathogenic variants in RYR2 are associated with death in sleep. 51 
 52 
KEYWORDS: Catecholaminergic ventricular tachycardia, cardiac ryanodine receptor, variant 53 
classification, arrhythmia.   54 
 55 
56 
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Introduction 57 
The rare monogenic arrhythmogenic disorder catecholaminergic polymorphic ventricular 58 
tachycardia (CPVT, MIM 604772) is characterised by episodic ventricular dysrhythmia triggered by 59 
exercise or emotion in individuals without structural cardiac defects (1). CPVT can be inherited in 60 
both an autosomal dominant form caused by heterozygous pathogenic variants in the cardiac 61 
ryanodine receptor gene (RYR2) (MIM 180902)(2), less frequently in CALM1 (MIM 114180)(3) 62 
encoding calmodulin 1 and autosomal recessive form due to biallelic variants in CASQ2 (MIM 63 
114251)(4) encoding calsequestrin, TRDN (MIM 603283)(5) encoding triadin and TECRL (MIM 64 
617242)(6). Furthermore, CPVT can also be caused by rare deletions in exon 3 of RYR2 (7). However, 65 
in such cases CPVT is often accompanied by left ventricular non-compaction (7). It is estimated that 66 
one in 10,000 people are clinically affected by the condition, with sudden cardiac death being the 67 
first manifestation in some individuals (1, 8, 9). The phenotypic heterogeneity of CPVT can delay or 68 
obscure diagnosis. It has been reported that almost one in three individuals with CPVT are initially 69 
diagnosed with long QT syndrome (LQTS) despite a normal QT interval (2). Consequently, combined 70 
approaches of cardiac assessment including exercise stress testing and genetic analysis are used to 71 
confirm a diagnosis of CPVT.  72 
The large coding region of the cardiac ryanodine receptor (105 exons) previously made genetic 73 
testing costly and time consuming using conventional DNA sequencing methods. As a result, it 74 
became common practice to only screen the four regions considered to be mutation hotspots in 75 
RYR2 (10). Next generation sequencing has now become more widely available and all coding exons 76 
of RYR2 can be screened rapidly and cheaply. This has led to an increase in the number of RYR2 77 
variants being reported in individuals with cardiac dysrhythmia or associated symptoms of 78 
palpitations, syncope or sudden unexplained death. Concomitant with this has been the increase in 79 
RYR2 variants identified in apparently healthy individuals collated through international resources, 80 
including the Genome Aggregation Database (gnomAD)(11). The majority of RYR2 variants are 81 
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missense changes. When assayed in functional experiments a number of these lead to increased 82 
channel activity consistent with pathogenicity. However, the rarity of these variants and complexity 83 
of functional assays makes it difficult to determine their pathogenicity, and so the majority are 84 
classified as variants of uncertain significance (VUS). Recently the American College of Medical 85 
Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP) proposed 86 
guidelines to standardise the classification of genetic variants (12). 87 
In this study we collate RYR2 variants reported in individuals with, or suspected of having CPVT, and 88 
classify them according to these ACMG guidelines and correlate the variants with clinical features.  89 
Methods 90 
A comprehensive search for RYR2 variants identified in individuals undergoing genetic testing for 91 
CPVT or an associated arrhythmia was performed. A total of 326 different RYR2 variants was 92 
obtained from the North West Genomic Laboratory Hub, UK (a service that has been undertaking 93 
clinical diagnostic testing of RYR2 for >10 years), the published literature and clinical variant 94 
databases, including ClinVar and the Human Gene Mutation Database (HGMD) (Supplementary 95 
Table 1) (13, 14). Allele frequencies of RYR2 variants in apparently healthy individuals were obtained 96 
from gnomAD as a comparator, accessed online from https://gnomad.broadinstitute.org (11).  97 
Phenotype-Genotype analysis 98 
All RYR2 variants both in control and CPVT populations were mapped to the domains, structural 99 
motifs and regions in which they are located in the RyR2 protein (using the universal protein 100 
resource (UniProt) accession number Q92736) with Mutation Mapper from the cBio Cancer 101 
Genomics Portal. For the purpose of our analysis RYR2 regions that were not associated with any 102 
known functional or structural domains were individually labelled as ‘no domain’ followed by a 103 
number ranging from 1 to 9 corresponding to their location.  The proportion of missense variants in 104 
each region/domain of RYR2 in control and CPVT populations were compared using the Fisher’s 105 
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exact test using GraphPad prism. To account for multiple testing a p-value < 0.005 was considered 106 
significant. 107 
Variant Classification 108 
RYR2 variants were classified based on the 2015 ACMG-AMP guidelines. As reported by Denham et 109 
al. (2019) 12 of the 27 criteria listed in the ACMG-AMP guidelines were excluded from this study as 110 
they were considered non-applicable (reasons for the exclusion of these criteria are included in 111 
Supplementary Table 2)  (15). The application of these guidelines has been previously reported 112 
(Supplementary Table 3 and 4)(15). 113 
Criteria for segregation 114 
The criteria for a variant to qualify for variant segregation (PP1) required that the variant was 115 
present in two or more members of the same family with a CPVT-like phenotype (arrhythmias, 116 
syncope, bradycardia or sudden death). The occurrence of affected individuals in whom the putative 117 
variant did not segregate was considered strong evidence for a benign classification (BS4).  118 
Criteria for functional studies 119 
Robust functional studies, including animal models, calcium imaging, cellular electrophysiology and 120 
single channel analysis showing either a significant reduction or gain of function, were considered 121 
strong evidence for pathogenicity (PS3). Conflicting functional data on variants was not considered 122 
as positive evidence of pathogenicity. Functional studies that reported no change in channel 123 
function were considered evidence for a benign classification (BS3). 124 
Criteria for variant frequency 125 
Variants that were absent from gnomAD were considered ultra-rare (PM2) and variants with an 126 
allele count of below 4 were considered rare.  127 
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The statistical framework used to identify variants that occur too frequently in the gnomAD 128 
database to be pathogenic has been described by Whiffin et al. (2017) (16). To summarize, it 129 
involves the determination of the maximum credible population allele frequency for a missense 130 
variant in RYR2 that causes CPVT. This was calculated based on CPVT as a dominant condition with a 131 
penetrance of approximately 60% (8). A binomial distribution of the maximum credible allele 132 
frequency was generated for our sample of CPVT cases (observed allele number) and the upper 133 
boundary of the 95% confidence interval (the maximum tolerated allele count) was used as the cut 134 
off frequency. Variants that occurred more frequently than the maximum tolerated allele count in 135 
gnomAD were considered common and this was strong evidence for a benign classification (BS1). 136 
Criteria for variant enrichment in CPVT cases 137 
Ultra-rare and rare variants were considered for variant enrichment analysis. The presence of an 138 
ultra-rare or rare variant in at least five or ten CPVT cases, respectively, was considered as strong 139 
evidence (PS4). 140 
Criteria for computational evidence 141 
To remain consistent with previously reported variant classification methods, five protein-level in 142 
silico prediction tools: SIFT, PolyPhen, Mutation Taster, Mutation assessor, FATHMM and three 143 
conservation tools GERP++, PhyloP conservation and SiPhy were used for the computational analysis 144 
of variants where DNA positional information was provided (GERP++, PhyloP, and SiPhy scores of 145 
4.4, 1.6, and 12.17, respectively were set as thresholds for conservation)(15). In addition, Consurf 146 
(http://consurf.tau.ac.il/), which uses advanced probabilistic evolutionary models to distinguish true 147 
conservation resulting from purifying selection and produces estimates for the credibility of the 148 
results, was used to measure conservation of amino acid positions of variants in controls and CPVT 149 
patients. The Consurf scores of the amino acid positions of control, CPVT and sudden death cases 150 
were compared using the Mann-Whitney test using GraphPad prism, p-value <0.005 was considered 151 
significant. 152 
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Criteria for critical functional domain 153 
The location of a missense variant in the transmembrane 4-6 region or ion-transport domain of the 154 
protein was considered as moderate evidence for a pathogenic classification, as the functional 155 
significance of these regions has been established (17, 18).  156 
Results 157 
Collation of RYR2 missense variants 158 
A total of 326 independent RYR2 single nucleotide, non-synonymous variants associated with CPVT 159 
or arrhythmia were identified. Of these variants 97 were present in both control and CPVT 160 
populations. Importantly, 104 (31.9%) of the CPVT-associated RYR2 variants were located outside of 161 
regions previously considered mutation hotspots. The hotspot regions with the most RYR2 variants 162 
were domains III and IV, where 21.5% and 21.2% of variants were located, respectively. The numbers 163 
of male and female cases were similar (Table 1). 164 
The most common amino acid position at which missense changes occurred was Arg420. Nineteen 165 
(19) of 440 (4.3%) independent cases were reported to have a missense change at this amino acid 166 
position, 10 cases carried the Arg420Trp variant and 9 carried the Arg420Gln variant. The second 167 
most common protein position for missense changes was Arg176, 8 of 440 (1.8%) cases carried the 168 
Arg176Gln variant.   169 
Genotype-Phenotype analysis 170 
Several domains or regions within RYR2 contained a significantly higher proportion of CPVT-171 
associated missense variants compared with controls (Figure 1 and Table 2). CPVT-associated 172 
missense variants occurred more frequently than expected between amino acid positions 3949-4332 173 
and 4867-4967 (No Domain regions 5 and 7). CPVT-associated RYR2 variants were also enriched in 174 
the RyR and IP3R homology-associated and ion transport domains when compared to control 175 
variants (p < 0.005). In contrast, control variants clustered between amino acid positions 2906-3826 176 
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and the SPRY and RYR domain when compared to CPVT-associated variants (p < 0.005). There was 177 
no clear relationship between sudden death and the location of CPVT-associated RYR2 variants 178 
(Figure 1A, Supplementary Table 5). However, five of the nine RYR2 variants associated with sudden 179 
death during sleep occurred in the C-terminus of the protein (Figure 1A, Supplementary Table 6). 180 
Conservation analysis 181 
CPVT variants occurred at positions with significantly higher Consurf scores than controls (P < 182 
0.0001), and variants identified in individuals or families with a history of sudden death had higher 183 
Consurf scores compared to variants in individuals and families without a history of sudden death (P 184 
< 0.0001) (Figure 2). This suggests variants with Consurf scores above 7 are more likely to be CPVT-185 
associated and of these variants those with Consurf scores above 8 are more likely to be associated 186 
with sudden death. 187 
Classification of RYR2 variants 188 
RYR2 variants were classified according to the ACMG-AMP guidelines and statistical methods were 189 
used to identify those variants that occurred too frequently in controls to be pathogenic, these 190 
variants were classified as benign (Supplementary Table 7). Using the statistical method described by 191 
Whiffin et al. (2017)(16), data on the most common CPVT-associated RYR2 variant c.1258C>T 192 
(Arg420Trp) and control populations from the ExAC or gnomAD databases, the maximum tolerated 193 
allele count for CPVT associated RYR2 variants was calculated (Supplementary Tables 8 and 9). 194 
The maximum tolerated allele count for pathogenic RYR2 variants was calculated to be two when 195 
using the ExAC database as a control population and three for the gnomAD database. Using the 196 
gnomAD database and the maximum tolerated allele count as a frequency threshold for 197 
pathogenicity 55 of 326 previously putative disease associated variants were re-classified as benign 198 
according to the ACMG guidelines, 11 fewer variants (44) were reclassified as benign using the ExAC 199 
database. A further 245 variants were classified as variants of uncertain significance, 14 as likely 200 
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pathogenic and 12 as pathogenic using gnomAD as the control comparator (Table 3). Both benign 201 
and pathogenic variants occurred most frequently outside of known functional domains. The ion 202 
transport domain contained the most (7 of the 26) pathogenic or likely pathogenic variants. The 203 
SPRY domain was found to be the domain containing the most benign variants; this domain did not 204 
contain any pathogenic variants. 205 
Sufficient functional data to aid classification was available for 50 of the 326 variants 206 
(Supplementary Table 10). The classification of the 26 variants deemed to be pathogenic/likely 207 
pathogenic was driven by absence from the gnomAD database (92%, P6), computational evidence 208 
(88%, P9), functional data (73%, P3) and de novo status (50%, P2). The classification of the 55 209 
variants classified as benign was largely driven by variant frequency in gnomAD exceeding the 210 
maximum tolerated allele count (100%, B2) and only one or none of the computational prediction 211 
tools indicating pathogenicity (11%, B5). 212 
Reason for referral and genetic testing outcome 213 
Cases referred for genetic testing at MCGM with a more confident diagnosis of CPVT based on 214 
clinical evaluation were tested using the CPVT genetic panel, whereas those cases with less 215 
diagnostic certainty were tested using either the arrythmia panel  (including 37 genes associated 216 
with inherited arrhythmia) or the molecular autopsy panel (61 genes associated with sudden cardiac 217 
death). The proportion of patients referred for genetic testing with the CPVT panel that carried RYR2 218 
variants was significantly greater than that of the patients tested with the arrhythmia panel (P < 219 
0.05) or molecular autopsy panel (P < 0.0005). Furthermore, these patients were more likely to carry 220 
pathogenic RYR2 variants (P < 0.05) (Table 4, Figure 3). 221 
Discussion 222 
The availability of sequence variant databases like gnomAD (11) and a statistical threshold to aid in 223 
the classification of pathogenicity for genetic variants (16) is aiding the robust classification of 224 
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sequence variants as associated, or not, with disease. The maximum tolerated allele count method 225 
was validated in individuals with hypertrophic cardiomyopathy using previous variant assessments 226 
and reports of pathogenicity in ClinVar (14). In the present study we used this method to calculate a 227 
maximum tolerated allele count for CPVT-associated RYR2 missense variants. Using this frequency 228 
threshold, 55 of 326 (16.9%) CPVT associated RYR2 variants were re-classified as benign. Thus, our 229 
data show a sizeable number of RYR2 variants are not disease-causing, in which case the proportion 230 
of CPVT cases attributable to RYR2 variants is likely to be over-estimated and the proportion of cases 231 
attributable to changes in other genes or to post-translational modifications is likely to be 232 
underestimated. The reclassification of VUS as benign variants is important as family members 233 
previously cascade tested to carry these variants may not be at increased risk and those without 234 
these variants may have been falsely reassured and remain at risk of arrhythmia or sudden cardiac 235 
death. Furthermore, this classification of benign variants offers the opportunity to find the real 236 
explanation for the CPVT phenotype in affected individuals. 237 
In the present study the maximum tolerated allele count for CPVT associated RYR2 missense variants 238 
was calculated using both the ExAC and gnomAD databases as control populations. Variants that 239 
occurred above the frequency threshold in each population where then reclassified accordingly. The 240 
ExAC database contains exome data from 60,706 unrelated apparently healthy individuals, whereas 241 
the gnomAD database contains combined exome and genome variant data from 141,456 individuals. 242 
Importantly 1600 of the 1975 (81%) RYR2 missense variants reported in gnomAD have a minor allele 243 
count below four. This not only highlights that a number of potentially healthy individuals have rare 244 
variants in RYR2 which may have a consequence in the context of a particular trigger e.g. exercise or 245 
emotion, but also that many benign RYR2 variants are rare. The utility of larger control datasets in 246 
reclassifying RYR2 variants was exemplified in this study. Comparison with the larger gnomAD 247 
database as a control population allowed the reclassification of 11 additional RYR2 variants as 248 
benign compared to ExAC. Further reclassification of VUSs may be achieved with larger sequence 249 
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datasets and by using data from individuals with more phenotype data and of older age to reduce 250 
the effects of non-penetrance. 251 
Applying Consurf, we found RYR2 variants present in CPVT patients occurred at amino acid positions 252 
that were significantly more conserved than those of control variants and the conservation of 253 
residues where CPVT sudden death variants occurred was even greater (Figure 2). The application of 254 
a frequency threshold in control datasets with the consideration of Consurf may be more 255 
informative than using each method independently and may be particularly useful for determining 256 
the probability of a rare variant being pathogenic or benign. 257 
Both RYR2 variants and CPVT are commonly associated with arrhythmias and/or sudden death 258 
triggered by exercise or stress. However, we noted RYR2 variants in individuals who died or 259 
experienced cardiac arrest while asleep. In these patients almost all of the RYR2 variants that were 260 
not classified as benign resulted in changes within the C-terminal of the protein, with the exception 261 
of one variant that occurred in the central domain. Although, limited by the small number of cases 262 
this data suggests pathogenic C-terminal RYR2 variants may pose a greater risk of sudden death at 263 
rest, particularly during sleep. This relationship between C- terminal variants and sudden death in 264 
sleep is novel and requires independent validation.  Sleep is considered a restful period but during 265 
rapid eye movement (REM) sleep, which accounts for approximately 20% of sleep time, sympathetic 266 
activity is increased and intense emotional states occur (19). Thus, sudden death during sleep in 267 
patients with RYR2 variants may be due to episodes triggered by increased sympathetic activity 268 
comparable to exercise or emotional stress. Contrastingly, specific RYR2 variants may exhibit 269 
properties that increase their sensitivity to other sleep related triggers like rises in hormones such as 270 
melatonin which has been shown to induce ventricular arrythmias (20, 21). Importantly in a recent 271 
prospective study of sudden cardiac death the majority of deaths occurred during sleep (22) and 272 
CPVT should be considered as a potential cause in this setting.  273 
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Our data shows that CPVT-associated RYR2 variants predominantly cluster in four regions/domains, 274 
namely the RyR and IP3R homology-associated domain; the ion transport domain; and two regions 275 
outside of known domains (No domain regions 5 and 7). Generally, these regions correspond to the 276 
previously-reported mutation hotspots. However, more than 30% of CPVT-associated RYR2 variants 277 
occurred outside of mutation hotspots, emphasising the importance of screening the entire coding 278 
region of RYR2 in patients suspected of having CPVT.  279 
The presence of functional data was a major driver of pathogenic classifications. However functional 280 
data was only available for 50 of the 326 CPVT associated variants. In addition to this the threshold 281 
of at least a 50% effect on channel function required for pathogenicity as applied by Denham et al. 282 
(2019) may not be applicable for RYR2 as there is no direct correlation between the magnitude of 283 
variant functional effect and disease phenotype in CPVT (15). Computational evidence and absence 284 
from control datasets were also major contributors to pathogenic classifications, similar to Denham 285 
et al. (2019), we used eight computational tools and applied a threshold of six tools predicting a 286 
pathogenic effect for pathogenic classification (15). This method was found to be more stringent and 287 
require more evidence for a pathogenic classification when compared to previous systems (15).  288 
A limitation of this study was the lack of systematically collected phenotype data and this will be 289 
required prospectively to identify effective means of combining clinical and genetic information to 290 
make accurate CPVT diagnoses. Nonetheless, based on the clinical indications considered our data 291 
shows specificity of testing (a surrogate for confidence in the underlying phenotype) correlates with 292 
the likelihood of identifying a relevant variant. Thus, although genetic testing is a useful aid in the 293 
diagnosis of CPVT rigorous clinical evaluations and the establishment of additional common 294 
phenotypic traits for CPVT is likely to increase the efficiency of genetic testing, identification of 295 
pathogenic variants and possibly improve the management of the condition.  296 
In summary, CPVT-associated RYR2 variants cluster in specific domains/regions, many of which are 297 
within, but not confined to, previously established mutation hotspots. CPVT-associated variants 298 
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occur at residues that are more evolutionarily conserved than controls, and RYR2 variants associated 299 
with sudden death occur at positions which are even more highly conserved. The application of a 300 
frequency threshold for pathogenicity, amino acid conservation scores and functional data aid 301 
distinguishing pathogenic and benign variants. However, the majority of CPVT variants remain 302 
classified as VUS. Therefore, additional approaches are required, including sharing of sequence data 303 
from affected individuals through Clinvar and other resources, generation of additional sequence 304 
data from healthy controls and use of sensitive high-throughput functional assays like saturation 305 
genome editing, with sufficient weight to drive pathogenic or benign classifications (23).  306 
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Titles and legends to figures 405 
Figure 1A. The distribution of missense variants in RYR2 in control population from the gnomAD 406 
database (A), CPVT (B), sudden death (C) and sudden death in sleep (D) populations. 407 
 408 
Figure 1B. Proportion of RYR2 variants in grouped domains in controls from the gnomAD database, 409 
CPVT, sudden death and sleep-associated sudden death populations. The number of cases in the 410 
sudden death and sleep-associated sudden death groups was limited, there were 47 sudden death 411 
cases and 7 sleep-associated sudden death cases.  412 
 413 
Figure 1C. Grouped domains of RYR2 in which the proportion of RYR2 variants was significantly 414 
different in controls from gnomAD compared to CPVT patients. **** and *** represent P < 0.0001 415 
and P < 0.005, respectively.  416 
 417 
Figure 2. A) Consurf scores of amino acid positions of CPVT variants compared to controls from 418 
gnomAD. B) Consurf scores of amino acid positions of non-sudden death CPVT variants compared to 419 
sudden death CPVT variants. **** represents P < 0.0001. 420 
 421 
Figure 3. A) Number of patients referred for genetic testing using the CPVT, arrhythmia or molecular 422 
autopsy panel with an RYR2 variant detected. B) Number of patients referred for genetic testing 423 
using the CPVT, arrhythmia or molecular autopsy panel with a pathogenic RYR2 variant detected. 424 
 Table 1. Pre-established RyR2 variant hotspot regions in CPVT. 
Variant hotspot 
region 
Residues 
 (amino acids) 
variants  
(% of total) 
n=326
de novo variants 
(%) 
n=40
Male:Female  
Ratio (%) 
I 77-466 35 (10.7) 7 (17.5) 56:44
II 2246-2534 48 (14.7) 6 (15) 50:50 
III 3778-4201 70 (21.5) 13 (32.5) 42:58
IV 4497-4959 69 (21.2) 10 (25) 41:59
Non-hotspot regions  104 (31.9) 4 (10) 47:53 
  
Table 2. Proportion of RYR2 variants in individual RYR2 domains or regions in controls from gnomAD, 
CPVT, sudden death and sleep-associated sudden death populations. 
 
Protein domain or region Length of region 
(delimiting amino acids) 
Control 
population 
from gnomAD 
database (%) 
CPVT (%) Sudden 
death 
(%) 
Sleep 
(%) 
Inositol 1,4,5-
trisphosphate/ryanodine 
receptor  
212 (10-222) 100 (5.1) 18 (5.5) 1 (1.6) 0 
MIR domain  173 (226-399) 78 (3.9) 9 (2.8) 1 (1.6) 0 
No domain #1 51 (400-451) 31 (1.6) 15 (4.6) 4 (6.3) 0
RYDR_ITPR domain #1  203 (452-655) 89 (4.5) 9 (2.8) 1 (1.6) 0 
SPRY domain #1  137 (671-808) 75 (3.8) 4 (1.2) 0 0 
RyR domain #1  91 (862-953) 39 (2.0) 2 (0.6) 1 (1.6) 1 (11.1) 
RyR domain #2  93 (975 - 1068) 46 (2.3) 0 0 0 
SPRY domain #2  120 (1099 - 1219) 60 (3.0) 3 (0.9) 0 0
SPRY domain #3  135 (1424 - 1559) 59 (3.0) 4 (1.2) 1 (1.6) 1 (11.1) 
No domain #2 564 (1560-2122) 282 (14.3) 21 (6.4) 5 (7.9) 0 
RYDR_ITPR domain #2 208 (2123 - 2331) 52 (2.6) 29 (8.9) 12 (19) 1 (11.1)
No domain #3 367 (2332-2699) 160 (8.1) 38 (11.7) 3 (4.7) 0 
RyR domain #3  93 (2700 - 2793) 34 (1.7) 3 (0.9) 0 0 
RyR domain #4  85 (2820 - 2905) 26 (1.3) 0 0 0 
No domain #4 920 (2906-3826) 352 (17.8) 16 (4.9) 2 (3.2) 0 
RyR and IP3R Homology 
associated  
121 (3827 - 3948) 19 (1.0) 11 (3.4) 4 (6.3) 0
No domain #5 383 (3949-4332) 133 (6.7) 64 (19.6) 10 (15.9) 1 (11.1) 
Ryanodine Receptor TM 
4-6  
266 (4333 - 4599) 96 (4.9) 20 (6.1) 8 (12.7) 2 (22.2) 
No domain #6 130 (4600-4730) 38 (1.9) 16 (4.9) 3 (4.7) 2 (22.2) 
Ion_transport domain  135 (4731 - 4866) 19 (1.0) 18 (5.5) 2 (3.2) 0 
No domain #7 100 (4867-4967) 10 (0.5) 21 (6.4) 1 (1.6) 1 (11.1)
Table 3. RYR2 variant classification based on the ACMG-AMP guidelines 
ACMG classification Number of CPVT associated 
RYR2 variants total = 326 (%) 
Benign 55 (16.9)
Variant of uncertain significance 245 (75.6)
Likely pathogenic 14 (4.1)
Pathogenic 12 (3.7)
 
 
Table 4. Outcome of genetic testing for patients referred for CPVT, arrhythmia and molecular 
autopsy panels to the Manchester Laboratory (MCGM). 
 CPVT panel Arrhythmia panel Molecular autopsy panel 
Patients tested 98 130 166 
Patients with RYR2 
variants  
20 11 8 
Patients with pathogenic 
RYR2 variants 
10 2 1 






